Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, ...

Spanish biotech Gyala Therapeutics has launched a Phase I/IIa clinical trial of its lead CAR-T therapy GYA01 after authorization from the Spanish Agency of Medicines and Medical Devices. The study ...

An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

Elias Jabbour, MD, is a board-certified hematologist-oncologist and internationally recognized leukemia specialist. He is a Professor of Medicine and Chief of the Acute Lymphoblastic Leukemia (ALL) ...

Acute lymphoblastic leukemia (ALL) is known as a pediatric leukemia, with approximately half of cases occurring in children. ALL is the most common childhood malignancy, representing 75% to 80% of ...

Scientists from the Children’s Hospital of Philadelphia (CHOP) report that they have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a ...

Asparlas (calaspargase pegol-mknl) is a long-acting prescription injection medicine used for people with a certain type of blood cancer known as acute lymphoblastic leukemia (ALL). It is approved in ...

It’s been 20 years since Andrea Richmond heard the words no parent ever wants to hear, twice: “Your child has cancer.” Two of ...

Researchers identify beta catenin protein degradation as a therapeutic vulnerability in B cell acute lymphoblastic leukaemia, supporting the repurposing of glycogen synthase kinase 3 beta inhibitors.